Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatment of Post Herpetic Neuralgia
Conditions
Interventions
SLC022
Placebo
Locations
19
United States
Sierra Vista, Arizona, United States
Mission Viejo, California, United States
Orlando, Florida, United States
Plantation, Florida, United States
Marietta, Georgia, United States
Oak Brook, Illinois, United States
Start Date
January 1, 2009
Primary Completion Date
October 1, 2009
Completion Date
November 1, 2009
Last Updated
July 30, 2009
NCT07000409
NCT06896994
NCT06232486
NCT06225960
NCT07367152
NCT01106716
Lead Sponsor
Solace Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions